{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=122",
    "query": {
      "condition": "Phase II",
      "page": 122
    },
    "page_size": 10
  },
  "pagination": {
    "page": 122,
    "page_size": 10,
    "total_count": 21427,
    "total_pages": 2143,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=123&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=121&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T10:38:03.868Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03654768",
      "title": "Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive"
      ],
      "interventions": [
        {
          "name": "Bosutinib",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nilotinib",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Imatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2018-10-24",
      "completion_date": "2028-07-01",
      "has_results": true,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-11-18T10:38:03.868Z",
      "location_count": 541,
      "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 320 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03654768"
    },
    {
      "nct_id": "NCT06315491",
      "title": "A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Platinum-resistant Ovarian Cancer",
        "Refractory Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "CBX-12",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cybrexa Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2024-09-25",
      "completion_date": "2025-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-11-18T10:38:03.868Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06315491"
    },
    {
      "nct_id": "NCT00005974",
      "title": "Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "alvocidib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NCIC Clinical Trials Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 18,
      "start_date": "2000-07-04",
      "completion_date": "2008-09-22",
      "has_results": false,
      "last_update_posted_date": "2020-04-08",
      "last_synced_at": "2026-11-18T10:38:03.868Z",
      "location_count": 1,
      "location_summary": "Duluth, Minnesota",
      "locations": [
        {
          "city": "Duluth",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005974"
    },
    {
      "nct_id": "NCT04523818",
      "title": "Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Stage I Gastric Cancer AJCC v8",
        "Clinical Stage IIA Gastric Cancer AJCC v8",
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Clinical Stage IVA Gastric Cancer AJCC v8",
        "Gastric Adenocarcinoma",
        "Pathologic Stage IB Gastric Cancer AJCC v8",
        "Pathologic Stage II Gastric Cancer AJCC v8",
        "Pathologic Stage IIA Gastric Cancer AJCC v8",
        "Pathologic Stage IIB Gastric Cancer AJCC v8",
        "Pathologic Stage III Gastric Cancer AJCC v8",
        "Pathologic Stage IIIA Gastric Cancer AJCC v8",
        "Pathologic Stage IIIB Gastric Cancer AJCC v8",
        "Pathologic Stage IIIC Gastric Cancer AJCC v8",
        "Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8",
        "Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8",
        "Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Therapeutic Surgical Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2020-08-11",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-11-18T10:38:03.868Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04523818"
    },
    {
      "nct_id": "NCT00813618",
      "title": "Study of MEDI 507 in the Treatment of Pediatric Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "MEDI-507",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 10,
      "start_date": "1999-09",
      "completion_date": "2004-08",
      "has_results": false,
      "last_update_posted_date": "2008-12-23",
      "last_synced_at": "2026-11-18T10:38:03.868Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Orange, California • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00813618"
    },
    {
      "nct_id": "NCT01050790",
      "title": "Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 17,
      "start_date": "2010-01",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2018-06-26",
      "last_synced_at": "2026-11-18T10:38:03.868Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01050790"
    },
    {
      "nct_id": "NCT01459497",
      "title": "Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Conventional radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 103,
      "start_date": "2012-10",
      "completion_date": "2023-10-19",
      "has_results": true,
      "last_update_posted_date": "2024-01-17",
      "last_synced_at": "2026-11-18T10:38:03.868Z",
      "location_count": 7,
      "location_summary": "Austin, Texas • Dallas, Texas • Houston, Texas + 4 more",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Irving",
          "state": "Texas"
        },
        {
          "city": "Sherman",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01459497"
    },
    {
      "nct_id": "NCT05191797",
      "title": "Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Extensive Stage Lung Small Cell Carcinoma",
        "Limited Stage Lung Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Bomedemstat",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2022-04-11",
      "completion_date": "2024-04-05",
      "has_results": true,
      "last_update_posted_date": "2024-09-26",
      "last_synced_at": "2026-11-18T10:38:03.868Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05191797"
    },
    {
      "nct_id": "NCT00952497",
      "title": "A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "Cisplatin, Capecitabine, Telatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ACT Biotech, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2009-06",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2012-02-08",
      "last_synced_at": "2026-11-18T10:38:03.868Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Macon, Georgia • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Macon",
          "state": "Georgia"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00952497"
    },
    {
      "nct_id": "NCT00254410",
      "title": "FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2005-03-14",
      "completion_date": "2017-09-14",
      "has_results": true,
      "last_update_posted_date": "2019-05-01",
      "last_synced_at": "2026-11-18T10:38:03.868Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00254410"
    }
  ]
}